


When Nonclinical Studies Need a Test Article Adjustment, Integration Matters



Keep formulation, stability, scale-up, and study execution connected with one integrated nonclinical and CDMO partner.



The Altasciences Advantage

Expertise

- Our CDMO supports small molecules and mid-sized modalities (e.g., peptides), agnostic to route of administration and therapeutic area
- Our experts have a deep understanding of molecular modalities and complexities within different molecules

Understanding

- Abreast in the OEL limits for the molecule
 - Our CDMO can support up to OEL 4 and are proficient in understanding the OEL limits for the molecule
 - We can support all schedules of compounds (I-V)

Alignment

- We align and ensure an early understanding of the nonclinical and first-in-human (FIH) strategy with formulation and drug product development
- We manage all logistics on behalf of the sponsor once the API is in house

Partnering

- As a fully integrated CRO/CDMO drug development partner, we work closely to guide nonclinical-to-clinical (FIH) bridging strategies
- We coordinate with our nonclinical sites to ensure the most cost-effective test article development and preparation

The proof is in the work. Check out a [case study](#) where a formulation pivot preserved a GLP study timeline.

